Your browser doesn't support javascript.
loading
Brief Report: Modeling the Impact of Voluntary Medical Male Circumcision on Cervical Cancer in Uganda.
Davis, Stephanie M; Habel, Melissa A; Pretorius, Carel; Yu, Teng; Toledo, Carlos; Farley, Timothy; Kabuye, Geoffrey; Samuelson, Julia.
Afiliação
  • Davis SM; Division of Global HIV/AIDS and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA.
  • Habel MA; Division of Global HIV/AIDS and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA.
  • Pretorius C; Modeling, Planning and Policy Analysis Center of Excellence, Avenir Health, Glastonbury, CT.
  • Yu T; Modeling, Planning and Policy Analysis Center of Excellence, Avenir Health, Glastonbury, CT.
  • Toledo C; Division of Global HIV/AIDS and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA.
  • Farley T; Sigma3 Services SÀRL, Nyon, Switzerland.
  • Kabuye G; Centers for Disease Control and Prevention, Kampala, Uganda; and.
  • Samuelson J; Department of HIV, AIDS and Hepatitis; Key Populations and Innovative Prevention Team, World Health Organization, Geneva, Switzerland.
J Acquir Immune Defic Syndr ; 86(3): 323-328, 2021 03 01.
Article em En | MEDLINE | ID: mdl-33136817
ABSTRACT

BACKGROUND:

In addition to providing millions of men with lifelong lower risk for HIV infection, voluntary medical male circumcision (VMMC) also provides female partners with health benefits including decreased risk for human papillomavirus (HPV) and resultant cervical cancer (CC).

SETTING:

We modeled potential impacts of VMMC on CC incidence and mortality in Uganda as an additional benefit beyond HIV prevention.

METHODS:

HPV and CC outcomes were modeled using the CC model from the Spectrum policy tool suite, calibrated for Uganda, to estimate HPV infection incidence and progression to CC, using a 50-year (2018-2067) time horizon. 2016 Demographic Health Survey data provided baseline VMMC coverage. The baseline (no VMMC scale-up beyond current coverage, minimal HPV vaccination coverage) was compared with multiple scenarios to assess the varying impact of VMMC according to different implementations of HPV vaccination and HPV screening programs.

RESULTS:

Without further intervention, annual CC incidence was projected to rise from 16.9 to 31.2 per 100,000 women in 2067. VMMC scale-up alone decreased 2067 annual CC incidence to 25.3, averting 13,000 deaths between 2018 and 2067. With rapidly-achieved 90% HPV9 vaccination coverage for adolescent girls and young women, 2067 incidence dropped below 10 per 100,000 with or without a VMMC program. With 45% vaccine coverage, the addition of VMMC scaleup decreased incidence by 2.9 per 100,000 and averted 8000 additional deaths. Similarly, with HPV screen-and-treat without vaccination, the addition of VMMC scaleup decreased incidence by 5.1 per 100,000 and averted 10,000 additional deaths.

CONCLUSIONS:

Planned VMMC scale-up to 90% coverage from current levels could prevent a substantial number of CC cases and deaths in the absence of rapid scale-up of HPV vaccination to 90% coverage.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Neoplasias do Colo do Útero / Circuncisão Masculina Tipo de estudo: Incidence_studies / Prognostic_studies / Screening_studies Limite: Adolescent / Female / Humans / Male País/Região como assunto: Africa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Neoplasias do Colo do Útero / Circuncisão Masculina Tipo de estudo: Incidence_studies / Prognostic_studies / Screening_studies Limite: Adolescent / Female / Humans / Male País/Região como assunto: Africa Idioma: En Ano de publicação: 2021 Tipo de documento: Article